CHRYSALIS-2 Trial

Atypical EETING In CHRYSALIS-2 receive 1L amiva Median age Most freque Compound 1 At a median follo CBRe was 8 Median DoF 0 -20 Change in SoD of target lesions (%) -40 -60 -80 -100 Figure reused with permission from Toma Participants may be counted in >1 categ 4 participants. CBR is defined as the per 1. Tomasini P, ot al. J Clin Oncol. 2026;4 2026 ASCO #ASC ANNUAL MEETING 2026 ASC ANNUAL MEETI --- CJ Conclusions CHRYSALIS 2 Atypical EGFR+ NSCLC This single-arm study of amivantamab + lazertinib (n=49) in 1L atypical EGFR-mutated advanced NSCLC demonstrates a clinically meaningful median os of ~3.5 years Responses were durable regardless of demographics, baseline tumor mutations, and disease characteristics With longer follow-up, the safety profile of IV amivantamab + lazertinib was consistent with prior reports¹,², with no new safety signals Amivantamab + lazertinib as a 1L treatment has now shown durable survival in both common and atypical EGFR-mutated advanced NSCLC 1. Tomanini P. at J Clin Oncol 2020 44(1).54- 2. Yang JCH, of a N Engl / Med. 2025,393(17) 1581-1693 2026 ASCO PRE SENTED BY: Joel W Neal Copies of his slide deck obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without ASCO AMERICAN ROCETY OF CUPICAL OHCOLOGY #ASCO26 ANNUAL MEETING Presentation a property of the author and ASCO Permission required for - contact permissions@assoo.or org permission from ASCO* or the authors of these sades KNOWLEDGE CONQUERS CANCER ASCO ASCO ASCO ASCO ASCO AS ASCO ASC ASCO ASCO ASCO ASCO CO SC ASCO AS

CHRYSALIS 2 CHRYSALIS-2 Study Design 1L Amt Laz in Atypical EGFR+ NSCLC Dose expansion cohorts Cohort A: EGFR Ex19del or L858R Post-osimertinib and platinum-based chemotherapy Cohort B: EGFR Ex20ins Previously reported¹ Dose escalation phase Post-standard of care and platinum-based chemotherapy Primary endpoint: RP2CD was identified: Cohort C: Atypical EGFR mutations ORR by investigator per IV amivantamab 1050 mg Treatment naïve or post-EGFR TKI/chemotherapy© RECIST v1.1 (1400 mg if >80 kg)ᵃ Cohort D: EGFR Ex19del or L858R plus Post-osimertinib, biomarker validation Secondary endpoints: DoR Cohort E: EGFR Ex19del or L858R Lazertinib 240 mg orally CBRc Post-osimertinib, MET IHC+ analysis (amivantamab + lazertinib) PFS Cohort F: EGFR Ex19del or L858R OS Post-osimertinib, MET IHC+ analysis (amivantamab monotherapy) Safety (AEs) Participants with Ex20ins and Ex19del/L858R co-mutations were excluded CHRYSALIS-2 enrolled prior to COCOON², SKIPPirr³, and PALOMA-34 Therefore, participants did not receive the enhanced prophylaxis for dermatologic AEs and IRRs, and subcutaneous amivantamab was not available CHRYSALIS-2 ClinicalTrials.g Identifier: NCT04077463 "Amivantamab was administered intravenously once every week during Cycle 1, with the first dose split between 2 days (350 mg once daily on C101, and the remainder on C1D2) and then every 2 weeks in subsequent cycles. Participants had received 52 previous lines of treatment with chemotherapy and/or second-generation EGFR TKI as the most recent line of therapy. CBR is defined as the percentage of participants achieving confirmed CR, PR, or durable SD (duration of 211 weeks). 1. Tomasini P. et al. Clin Oncol. 2026;44(1):54-65. 2 Cho BC, et al. J Thorac Oncol. 2025,20(10):1517-1530. 3. Spira AI, et al. J Thorac Oncol 2025,20(6) 809-816 4. Leight NB, et al. Clin Oncol 2024;42(30) 3593-3605 PRESENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) 2026 ASCO #ASCO26 Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY or CURICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org permission from ASCO® or the authors of these slides KNOWLEDGE CONQUERS CANCER --- Radiographic Response With 1L Amivantamab + Lazertinib in CHRYSALIS 2 1L Amt Laz in Atypical EGFR-Mutated NSCLC¹ Atypical EGFR+ NSCLC In CHRYSALIS-2 Cohort C, a total of 49 treatment-naïve participants with atypical EGFR-mutated NSCLC were enrolled globally to receive 1L amivantamab + lazertinib Median age was 60 years, 45% were female, and 57% were Asian Most frequent EGFR mutationsᵃ included G719Xb (55%), S768Xc (27%), and L861Xd (24%) Compound mutations were observed in 35% of tumors At a median follow-up of 16.1 months, ORR was 57% CBRe was 84%, and all evaluable patients with ≥1 post-baseline assessment achieved PR or SD Median DoR was 20.7 months and median PFS was 19.5 months (95% CI, 11.2-NE) 0 -20 Change in SoD of target lesions (%) -40 PR SD -60 -80 -100 Figure reused with permission from Tomasini P, et al. Amivantamab Plus Lazertinib in Atypical EGFR-mutated Advanced Non-Small Cell Lung Cancer Results From CHRYSALIS-2 Journal of Clinical Oncology 2026 44(1)54-65 Participants may be counted in 21 category. "Included G719A G719S, and G719C Compound mutations were observed in 14 participants. included S7681 and S768L Compound mutations were observed in 11 participants included L861Q L861R, and L861G Compound mutations were observed in 4 participants. *CBR is defined as the percentage of participants achieving confirmed CR, PR, or durable SD (duration of >11 weeks). Five participants (NE, n=1; PD, n=2 SD, n=2) without # postbaseline tumor assessment are not shown All participants wore included in the ORR analysis. 1. Tomasini P. et al. J Clin Oncol 2026;44(1):54-65. 2026 ASCO PRESENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) #ASCO26 Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY of CLINICAL DHCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org permission from ASCO or the authors of these stides KNOWLEDGE CONQUERS CANCER --- Overall Survival CHRYSALIS-2 1L Ami Laz in Atypical EGFR+ NSCLC 100 85% 80 72% Participants who are surviving (%) 60 55% 40 Median os Median follow-up, 31.3 mo (95% CI) Amivantamab 41.0 mo (27.7-NE) + lazertinib 20 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 Months No. at risk mivantamab lazertinib 49 44 37 37 36 36 36 34 29 27 26 22 19 15 10 10 8 1 0 2026 ASCO PRESENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) #ASCO26 ASCO AMERICAN SOCIETY OF Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org permission from ASCO or the authors of these stides KNOWLEDGE CONQUERS CANCER --- Time on Treatment With Atypical EGFR Mutation Type CHRYSALIS. 2 1LAm + Laz in Atypical EGFR+ NSCLC Local data G719X S768X 861X Other Compound PR SD PD Ongoing PO. 0 6 12 18 24 30 36 42 48 54 Time on treatment (months) 2026 ASCO PRESENTED BY: Joel W Neal Copies of this stide deck obtained through Quick Response (QR) ASCO AMERICAN SOCIETY OF #ASCO26 Code are for personal use only and may not be reproduced without CUNICAL CHICOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org permission from ASCO® or the authors of these studes KNOWLEDGE CONQUERS CANCER

CHRYSALIS-2 Study Design CHRYSACIS-2 esser MOOLC Dose expansion cohorts Cohort A: EGFR Ex19del or L858R Post-osimertinib and platinum-based chemotherapy Cohort B: EGFR Ex20ins Dose escalation phase Post-standard - of care and platinum-based chemotherapy Previously reported1 RP2CD was identified: Cohort C: Atypical EGFR mutations Primary endpoint: IV amivantamab 1050 mg Treatment naive or post-EGFR TKI/chemotherapy® ORR by investigator per (1400 mg if >80 kg)a RECIST v1.1 Cohort D: EGFR Ex19del or L858R plus Post-osimertinib, biomarker validation Secondary endpoints: DoR Cohort E: EGFR Ex19del or L858R Lazertinib 240 mg orally CBR Post-osimertinib, MET IHC+ analysis (amivantamab + lazertinib) PFS Cohort F: EGFR Ex19del or L858R OS Post-osimertinib, MET IHC+ analysis (amivantamab monotherapy) Safety (AEs) Participants with Ex20ins and Ex19del/L858R co-mutations were excluded CHRYSALIS-2 enrolled prior to COCOON2, SKIPPirr³, and PALOMA-34 Therefore, participants did not receive the enhanced prophylaxis for dermatologic AEs and IRRs, and subcutaneous amivantamab was not available Identifier: NCT04077463 Amivantamab was administered intravenously once every week during Cycle 1, with the as first the dose spit between of 2 days (350 achieving mg ance confirmed daily on C101, CR, PR, and of the durable remainder SD /duration on C C102) of 211 and weeks) then every 2 in subsequent cycles Participants had CHRYSALIS-2 ClinicalTrials lines of gov treatment with chemotherapy and/or second-generation EGFR TKI as the most recent line of therapy. CBR is defined percentage participants Clin Oncol 2024,42(3) 3593-3605 received 1. Tomasini <2 P. previous et al. J Clin Oncol 2026;44(1):54-65. 2. Cho BC, of al. J Thorac Oncol 2025,20(10) 1517-1530 3 Spira Al, et al. J Thorac Oncol 2025,20(8) 809-816 4 Leight NB, d. Copies of This as obtained through Quick Response OR) ASCO was CHICA - ASCO PRESENTED BY: Joel W Neal Code are for personal use only and may not be reproduced without Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco org permission from ASCO® or the authors of these sides ENQWLEDGE CONQUERS CANCER #ASCO26 MEETING 2026ASCO ANNUAL MEETING ASCO ASCO ASCO --- diographic Response With 1L Amivantamab + Lazertinib in CHRYSALIS Atypical EGFR-Mutated NSCLC1 NSCLC 2026 In CHRYSALIS-2 Cohort C, a total of 49 treatment-naïve participants with atypical EGFR-mutated NSCLC were enrolled globally to ANNUA receive 1L amivantamab + lazertinib Median age was 60 years, 45% were female, and 57% were Asian Most frequent EGFR mutations included G719Xb (55%), S768Xc (27%), and L861Xᵈ (24%) Compound mutations were observed in 35% of tumors At a median follow-up of 16.1 months, ORR was 57% CBRe was 84%, and all evaluable patients with ≥1 post-baseline assessment achieved PR or SD Median DoR was 20.7 months and median PFS was 19.5 months (95% CI, 11.2-NE) 0 -20 Change in SoD of target lesions (%) -40 PR SD -60 -80 Figure Participants reused may CBR with be permission IS counted defined in from as -100 21 the category Tomasini percentage Included P. et al of participants Amivantamab G719A G719S, achieving Plus and Lazertinib confirmed G719C in Compound CR Atypical PR, or EGFR mutations durable mutated SD were (duration Advanced observed 211 Non-Small in 14 weeks). participants Cell Five Lung participants included Cancer Results $7681 NE, at and From PD. S768L CHRYSALIS-2 n-2, Compound SD, n=2) without mutations Journal postbaseline of - Clinical observed Oncology fumor deck 11 atternment 2026,44(1) 54-6 participants obtained an through 9nduded L9E1Q not stown Quick Response participants L861R and LB6NG (QR) without - included e Compound be ASCO analysis - I Copies of TUS stide only and not be reproduced CHOWLEDGE CONQUERS CANCER 4 1. participants. Tomasini P. J Clin Oncol 2026,44(1):54-65. permission Code are for from personal ASCO* or the authors these sades. SCO #ASCO26 PRE Presentation property of he author and ASCO Permission required for reuse. contact SENTED BY: Joel W Neal MEETING 2026ASCO ASCO ANNUAL MEETING ASCO ASCO ASCO O ASCÓ ASCO --- Overall Survival CHRYSALIS-2 Anypical EGFA+ NOCLC 100 85% 80 72% Participants who are surviving (%) 60 55% Median os 40 Median follow-up, 31.3 mo (95% CI) Amivantamab 41.0 mo (27.7-NE) + lazertinib 20 0 18 21 24 27 30 33 36 39 42 45 48 51 54 0 3 6 9 12 15 Months No. at risk 34 29 27 26 22 19 15 10 10 8 1 0 ivantamab lazertinib 49 44 37 37 36 36 36 Copies of this side deck obtained through Quick Response (QR) ASCO SINCAL exclusive PRESENTED BY: Joel W Neal Code are for personal use only and may not be reproduced whoul KNOWLEDGE CONQUERS CANCER ASCO permission from ASCO* or the authors of these sides #ASCO26 Presentation is property of the author and ASCO Permission required for contact permissions@asco org AL MEETING 2026ASCO ANNILIAL MEETING --- Time on Treatment With Atypical EGFR Mutation Type CHRYSALIS-2 NSCLC 2020 Local data ANN G719X S768X L861X Other Compound PR SD PD Ongoing PD 24 30 36 42 48 54 6 12 18 0 Time on treatment (months) Copies of his slot deck obtained through Quick Response (QR) ASCO OREA Code are for personal use only and may not be reproduced without KNOWLEDGE CONQUERS CANCER PRESENTED BY: Joel W Neal permission bom ASCOR or the authors of these sades ASCO #ASCO26 Presentation is property of the author and ASCO. Permission required for reuse contact permissions@asco.org AL MEETING 2026ASCO ANNUAL MEETING ASCO ASCO ASCO

ASCO CHRYSALIS. 2 2026 Amt Laz in Atypical EGFR* ANNUAL MEETING NSCLC Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced NSCLC Updated results from the CHRYSALIS-2 study Joel W Neal1, Byoung Chul Cho², Yongsheng Wang³, Lin Wu⁴, Enriqueta Felip⁵, Jiuwei Cui⁶, Alexander I Spira⁷, Melina E Marmarelis⁸, Eiki Ichihara⁹, Se-Hoon Lee¹⁰, James Chih-Hsin Yang¹¹, Sebastian Michels¹², Joshua C Curtin¹³, Xuesong Lyu14, Zacharias Anastasiou¹⁵, Isabelle Leconte¹⁶, Leonardo Trani¹³, Sujay Shah¹³, Pascale Tomasini¹⁷ Stanford Cancer Institute, Stanford University, Stanford, CA USA Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Division of Thoracic Tumor Multimodality Treatment, Cancer Center and Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, China; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Medical Oncology Service, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Universitat Autónoma de Barcelona, Barcelona, Spain; The First Hospital of Jilin University, Changchun, China Virginia Cancer Specialists, Fairfax, VA, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, "National Taiwan University Cancer Center, Taipei, Towan, Department I for Internal Medicine, Faculty of Medicine and University Hospital Cologne, Lung Cancer Group Cologne, Center for Integrated Oncology Aachen Koin Bonn Düsseldorf, University of Cologne, Cologne, Germany, "Johnson & Johnson, Spring House, PA, USA; "Johnson & Johnson, Shanghai, China, "Johnson & Johnson, Alhers, Greece, "Johnson & Johnson, Allschwil, Switzerland "Aix Marseille University - CNRS, INSERM, CRCM, CEPCM- AP-HM Hôpital de la Timone, Marseille, France 2026 ASCO #ASCO26 PRE SENTED BY: Joel W Neal Copies of this Mde deck obtained through Quick Response (QR) ANNUAL MEETING ASCO AMERICA MN SOCIETY of Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY Presentation is property of the author and ASCO Permission required for reuse, contact permissions@esico.or permission from ASCO or the authors of these sides. KNOWLEDGE CONQUERS CANCER in atypical EGFR-mutated advanced NSCLC Updated results from the CHRYSALIS-2 study --- CHRYSALIS 2 CHRYSALIS-2 Study Design 1L Amt Laz in Atypical EGFR+ NSCLC Dose expansion cohorts Cohort A: EGFR Ex19del or L858R Post-osimertinib and platinum-based chemotherapy Cohort B: EGFR Ex20ins Previously reported1 Dose escalation phase Post-standard of care and platinum-based chemotherapy Primary endpoint: RP2CD was identified: Cohort C: Atypical EGFR mutations ORR by investigator per IV amivantamab 1050 mg Treatment naïve or post-EGFR TKI/chemotherapyᵇ RECIST v1.1 (1400 mg if >80 kg)ᵃ Cohort D: EGFR Ex19del or L858R plus Post-osimertinib, biomarker validation Secondary endpoints: DoR Lazertinib 240 mg orally Cohort E: EGFR Ex19del or L858R CBRc Post-osimertinib, MET IHC+ analysis (amivantamab + lazertinib) PFS Cohort F: EGFR Ex19del or L858R OS Post-osimertinib, MET IHC+ analysis (amivantamab monotherapy) Safety (AEs) Participants with Ex20ins and Ex19del/L858R co-mutations were excluded CHRYSALIS-2 enrolled prior to COCOON², SKIPPirr³, and PALOMA-34 Therefore, participants did not receive the enhanced prophylaxis for dermatologic AEs and IRRs, and subcutaneous amivantamab was not available CHRYSALIS-2 ClinicalTrials gov identifier: NCT04077463 "Amivantamab was administered intravenously once every week during Cycle 1, with the first dose split between 2 days (350 mg once daily on C1D1, and the remainder on C102) and then every 2 weeks in subsequent cycles. Participants had received 52 previous lines of treatment with chemotherapy and/or second generation EGFR TKI as the most recent line of therapy. CBR is defined as the percentage of participants achieving confirmed CR, PR, or durable SD (duration of 211 weeks). 1. Tomasini P. et al. Clin Oncol 2026;44(1).54-65. 2 Cho BC, et al. J Thorac Oncol. 2025,20(10):1517-1530. 3. Spira Al, et al. J Thorac Oncol 2025;20(6) 809-816. 4. Leight NB, etal.J Clin Oncol 2024,42(30),3593-3605 2026 ASCO PRESENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY OF #ASCO26 CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org. permission from ASCO or the authors of these slides KNOWLEDGE CONQUERS CANCER CO HRYSALIS-2 Study Design 2026ASCO ANNUAL MEETING CHRYSALIS-2 Study Design If Statement Detert --- Overall Survival CHRYSALIS-2 Адурісай EGFR+ NSCLC 100 85% 80 72% Participants who are surviving (%) 60 55% 40 Median os Median follow-up, 31.3 mo (95% CI) Amivantamab 41.0 mo (27.7-NE) + lazertinib 20 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 Months No. at risk Amivantamab lazertinib 49 44 37 37 36 36 36 34 29 27 26 22 19 15 10 10 8 1 0 PRESENTED BY: Joel W Neal Copies of this sade deck obtained through Quick Response (QR) ASCO AMERICAN SOURTY CR 2026 ASCO #ASCO26 Code are for personal use only and may not be reproduced without CLAIM OHCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco. org permission from ASCO or the authors of these sides KHOWLEDGE CONQUERS CANCER --- Time on Treatment With Baseline Characteristics CHRYSALIS-2 1LAml LIZ in Adypical EGFR+ NSCLC The median duration of treatmentᵃ with 1L amivantamab + lazertinib was 13.3 months (range, <0.1-53.2) 39% of 1L participants remained on treatment for >2 years >65 y Asian CNS PR SD PD Ongoing FOR 12 18 24 30 36 42 48 54 0 6 Time on treatment (months) "Treatment duration is defined as the duration from the day of the first dose of study drug to the day after the last dose of study drug Copies of this slide deck obtained through Quick Response (QR) ASCO AMERICAN SOCIETY OF CUMICAL DHCOLDER PRESENTED BY: Joel W Neal Code are for personal use only and may not be reproduced without 2026 ASCO KNOWLEDGE CONQUERS CANCER #ASCO26 Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org permission from ASCO or the authors of these slides ANNUAL MEETING

Frontline phase III trials for EGFR exon 20 insertions PAPILLON (n=308) EXCLAIM-2 (n=354) WU-KONG 28 (n=324) Arms Amivantamab+chemo V Mobocertinib V chemotherapy Sunvozertinib V chemotherapy chemotherapy Drug Bispecific lgG antibody Pyrimidine-based small molecule Pyrimidine-based small molecule Dosing iv/subcut q3 weekly Oral, daily Oral, daily (300 mg) Patient Brain mets: 23% V 23% Brain mets: 33% V 31% Brain mets: 12.9 V 12.4% characteristics Never smoker: 58 V 59% Never smoker: 54% V 61% Never smoker: 62 V 66.5% Efficacy ORR: 73% V 47% ORR: 32% V 30% ORR: 58.8% V 31.1% PFS: 11.4 V 6.7 m PFS: 9.6 V 9.6 m PFS: 10.3 V 7.5 m DoR: 9.7 V 4.4 m DoR: 12.0 V 8.4 m DoR: 11.2 V 7.1 m Toxicities Neutropenia: 59%/33% Diarrhoea: 96%/ 20% Diarrhoea: 84%/13.5% (All grades/ G3) Paronychia: 56%/7% Paronychia: 47%/ 1% Rash: 51.5%/0.6% Rash: 54%/ 11% Stomatitis: 40%/ 4% Anaemia: 46%/ 6.1% Stomatitis: 25%/ 1% Acneiform rash: 35%/1% CPK increase 55.2%/20.2% Paronychia: 48.5%/3.7% Dose interruption: 64% Dose interruption: 70% Dose reduction: 36% Dose reduction: 45% Drug interruption: 45.4% Discontinuation: 11% Discontinuation: 18% Dose reduction: 40.5% Discontinuation: 7.4% Girard NEJM 2023; Janne JCO 2025; Heymach ASCO 2026 026 ASCO PRE SENTED BY: Daniel SW Tan, National Cancer Centre Singapore ASCO AMERICAN SOCIETY OF #ASCO26 CLINICAL CHEDLOGY NNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco KNOWLEDGE CONQUERS CANCER --- Therapeutic advances in EGFR ex20 ins mutations - - EXCLAIM EXCLAIM-2 Accelerated approval PFS adents - - " Mobocertinib vs - mobocertinib Chemo - Structural basis PFS: 9.6 V 9.6 m . , 4 . " " . 11 24 If - a resistance to 1G Time months) EGFR TKI in Ex20 CHRYSALIS insertions Accelerated approval Roubichoux et al. WU-KONG 1B Yasuda STM 2013 - amivantamab Structural-functional Accelerated approval (monotherapy) basis classification - Sunvozertinib 200 mg 2013 2015 2017 2019 2021 2023 2024 2025 2026 Yang et al. Role of Osimertinib 160 mg OM PAPILLON FAVOUR WU-KONG 28 afatinib in uncommon POSITION20 SoC chemo- Firmonertinib Phase III mutations (LUX-2, ORR 28%, mPFS 6.8 m amivantamab ORR 78,6% Sunvozertinib 300 mg LUX-3, LUX-6) - - 3 cohorts: Exon 20 ECOG ACRIN EA5162 mDoR 15.2 m vs chemo A handred, blinded Independent Central ins/atypicals/ T790M ORR 24%, mPFS 9.6 m to Patients Limited efficacy for 10 14-7.21 afatinib in exon 20 ins # - is 35-4 12 is is n 24 Henths - - ($) us - N - 0 0 1 : - 1 as an 24 42 14 4 I a 6 2026 ASCO PRE SENTED BY: Daniel SW Tan, National Cancer Centre Singapore ASCO AMERICAN SOCIETY OF #ASCO26 CLINICAL CHCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse contact permissions@asco KNOWLEDGE CONQUERS CANCER --- Upfront RT did not reduce intracranial PFS Intracranial PFS PFS Overall survival UPPRONT RT + Delayed RT State - UPFRONT AT - Delayed RT - UPPRONT RT - Delayed ST 16 1.0 1.0 Protosty OF OD 0.8 Cumulative Survival Probability 0.8 04 Cumulative Survival Probability 0.8 06 06 04 0.4 0.2 0.2 0.2 0 0 12 11 24 30 30 00 00 Time months 0 6 12 18 24 30 30 Time months 0 6 12 18 24 30 30 Number et risk Time months 135 87 85 37 26 15 7 Number risk Number at nuk DONNERS 103 47 53 32 22 12 $ " 30 Strata UPFRONCE 105 87 65 37 26 15 7 . C 21 X & 103 87 55 32 22 12 8 UPPRONT #1 105 10 71 45 34 23 14 Time months 9 1 4 4 24 30 XI Delivery 103 R 74 59 41 25 17 Time months 0 $ Q 0 H # . Time months Median icPFS 18.2 V 14.8 m Median PFS 12.7 V 12.0 m Median os 23.3 V 28.7 m HR 0.82 (0.59 — 1.16) p 0.26 HR 1.05 (0.76 — 1.44) 0.75 HR 1.45 p 0.07 Treatment 0.70 Delayed RT - UPFRONT RT 0.65 0.00 Upfront RT (n=105) Delayed RT (n=103) Intracranial progression 111 0.50 Cumutative Incidence 0.45 Number of Events 20 47 "death as competing event 0.40 0.33 1-year 0.30 8.7% 2.9%,14.5%) 25.7% (16.8%,34.7%) 0.23 [exploratory analysis] 0.23 2-years 21.7% (12.6%,30.8%) 50% (39.2%,60.9%) 013 0.12 0.03 Sub-HR(95% CI) 0.35(0.21,0.59) p-value = <0.001 0.00 0 6 12 11 24 30 % Time (months) 26 ASCO PRESENTED BT: Daniel SW Tan, National Cancer Centre Singapore #ASCO26 ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY NUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco org With death as a competing event CONQUERS CANCER --- Expanding role of high-quality clinical registries for HTA assessments especially in rare diseases Median as (95% C) 100 Amirantamab isrertinio Median os Physician selected CFR- TIO 19.6 m (5.6-52.7) (95% Ca Amivantamab lazertinit 41.0 mo (27.7-NE) (%) Participants 1 : 100 75 Physician-sected EGFRTIO 75 Anivartanch 25 Physician-selet (CFR no Patients who are alive (%) - 50 Anivantamab lazertinis - 50 Median follow-up: 25 Amivantamab 31.3mg Physician selected (CFIL TX) Physician-selected CFR TXL 124mg 0 HR,0.29, 95% a 0.12-071; Pv0.015 0 6 12 18 24 30 36 42 48 54 0 Months 0 6 12 18 24 30 36 - I I : : : : : : : : : Months No. at eisk Amixantamob questions 43 34 36 23 12 2 c Physician-selected 50 45 8 21 19 16 10 2 Is Flatiron representative? - Multi-national database¹ (n=339) mos 20.3 m for single PACC Propensity score model²: ~85% received 1/2/3G TKI mOS Age, ECOG, brain mets at baseline, history of smoking, - NCCS (n=316) mOS 19.7 m (16.7-24.9) stage IIB/ IV, number of metastatic sites ~65% received 1/2/3G EGFR TKI Further improvements in cost-benefit ratio: SC delivery, biomarker directed use, response adapted treatment duration/ intervals 2026 ASCO PRE SENTED BY Daniel SW Tan, National Cancer Centre Singapore Monaca et al. ELCC 2026; Tomasini et al JCO 2025 #ASCO26 ASCO AMERICAN SQOETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse contact pennissions@asco.org KNOWLEDGE CONQUERS CANCER

2026ASCO ANNUAL MEETING AS --- Radiographic Response With 1L Amivantamab + Lazertinib in CHRYSALIS 1L Ami Laz in Atypical EGFR-Mutated NSCLC1 Atypical EGFR+ NSCLC In CHRYSALIS-2 Cohort C, a total of 49 treatment-naïve participants with atypical EGFR-mutated NSCLC were enrolled globally to receive 1L amivantamab + lazertinib Median age was 60 years, 45% were female, and 57% were Asian Most frequent EGFR mutations included G719Xb (55%), S768Xc (27%), and L861Xd (24%) Compound mutations were observed in 35% of tumors At a median follow-up of 16.1 months, ORR was 57% CBRe was 84%, and all evaluable patients with ≥1 post-baseline assessment achieved PR or SD Median DoR was 20.7 months and median PFS was 19.5 months (95% CI, 11.2-NE) 0 -20 Change in SoD of target lesions (%) -40 PR SD -60 -80 -100 Figure reused with permission from Tomasini P. et al Amivantamab Plus Lazertinib in Atypical EGFR mutated Advanced Non Small Cell Lung Cancer Results From CHRYSALIS-2 Journal of Clinical Oncology 2026,44(1):54-65 https://ascopabs.org/doi/10 1200/JCO-24-02835 Participants may be counted in 21 category "Included G719A G7198 and G719C Compound mutations were observed in 14 participants 'Included S7681 and S768L Compound mutations were observed in 11 participants included L861Q L861R and LB61G Compound mutations were observed in 4 participants "CBR is defined as the percentage of participants achieving confirmed CR PR, or durable SD (duration of 211 weeks) Five participants (NE, n=1, PD, n=2 SD. n=2) without a postbaseline tumor assessment are not shown All participants were included in the ORR analysis 1. Tomasini P. of al J Clin Oncol 2026;44(1) 54-65 2026 ASCO PRE SENTED BY: Joel W Neal Copies of this stide deck obtained through Quick Response (QR) #ASCO26 ASCO AMERICAN SOCIETY OF Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@as.co.org permission from ASCO* or the authors of these slides KNOWLEDGE CONQUERS CANCER --- Overall Survival CH 1L Aty 100 85% 80 72% Participants who are surviving (%) 60 55% Median os 40 Median follow-up, 31.3 mo (95% CI) Amivantamab 41.0 mo (27.7-NE) + lazertinib 20 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 5 Months No. at risk Amivantamab lazertinib 49 44 37 37 36 36 36 34 29 27 26 22 19 15 10 10 8 1 0 2026 ASCO PRESENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without ASCO AMERICA #ASCO26 CUNICA ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org permission from ASCO* or the authors of these stides KNOWLEDGE CONQUE --- Time on Treatment With Atypical EGFR Mutation Type CHRYSALIS 2 1L Amt Laz in Atypical EGFR+ NSCLC Local data G719X S768X L861X Other Compound PR SD PD Ongoing 0 6 12 18 24 30 36 42 48 54 Time on treatment (months) 2026 ASCO PRE SENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) ASCO AMERICAN SOCIETY OF #ASCO26 Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org permission from ASCO* or the authors of these slides KNOWLEDGE CONQUERS CANCER

CHRYSALIS 2 Overall Survival 1L Ami Laz in Alypical EGFR+ NSCLC 100 85% 80 72% Participants who are surviving (%) 60 55% Median os 40 Median follow-up, 31.3 mo (95% CI) Amivantamab 41.0 mo (27.7-NE) + lazertinib 20 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 Months No. at risk vantamab . lazertinib 49 44 37 37 36 36 36 34 29 27 26 22 19 15 10 10 8 1 0 2026 ASCO PRESENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY OF #ASCO26 CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco org. permission from ASCO® or the authors of these slides. KNOWLEDGE CONQUERS CANCER --- Time on Treatment With Baseline Characteristics CHRYSALIS. 2 1L Ami Laz in Atypical EGFR+ NSCLC The median duration of treatmentᵃ with 1L amivantamab + lazertinib was 13.3 months (range, <0.1-53.2) 39% of 1L participants remained on treatment for >2 years ≥65y Asian CNS PR SD PD Ongoing 0 6 12 18 24 30 36 42 48 54 Time on treatment (months) "Treatment duration is defined as the duration from the day of the first dose of study drug to the day after the last dose of study drug. 2026 ASCO PRESENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) #ASCO26 ASCO AMERICAN SOCIETY OF Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asoo org. permission from ASCO or the authors of these slides, KNOWLEDGE CONQUERS CANCER --- CHRYSA Conclusions 1L Ami + Atypical 1 NSC This single-arm study of amivantamab + lazertinib (n=49) in 1L atypical EGFR-mutated advanced NSCLC demonstrates a clinically meaningful median os of ~3.5 years Responses were durable regardless of demographics, baseline tumor mutations, and disease characteristics With longer follow-up, the safety profile of IV amivantamab + lazertinib was consistent with prior reports¹,², with no new safety signals Amivantamab + lazertinib as a 1L treatment has now shown durable survival in both common and atypical EGFR-mutated advanced NSCLC Tomasini P, of al. J Clin Oncol 2026;44(1):54-65. 2. Yang JCH, et of Engl / Med. 2025,393(17) 1681-1693 ASCO PRESENTED BY: Joel W Neal #ASCO26 Copies of this slide deck obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without ASCO AMERICAN SO CLINICAL ONC --- Also at ASCO 2026 CHRY 1L Am Atypic NS May 30th 9:00am-12:00pm May 31st 8:00am-11:00am Gastrointestinal Cancer - Colorectal and Anal Head and Neck Cancer Poster Session: Hall A Oral Abstract Session: S100a Abstract 3548 RIGAMI-1 Abstract 6008 Poster board 315 RIGAMI-4 Oral presentation Antitumor activity of amivantamab by consensus Amivantamab in HPV-unrelated R/M HNSCC after disease molecular subtypes in RAS/RAF WT mCRC progression on checkpoint inhibitor and chemotherapy (M Cruz-Correa) (B Burtness) May 30th 1:30pm-4:30pm May 31st 9:00am-12:00pm Head and Neck Cancer Lung Cancer - Non-Small Cell Metastatic Poster Session: Hall A Poster Session: Hall A Abstract 6038; Poster board 495 Abstract 8613; Poster board 403 Real-world treatment patterns and overall survival in R/M HNSCC following treatment with ICI SC amivantamab + lazertinib with and platinum-based chemotherapy (AJ Rosenberg) supportive care in 1L EGFRm COPERNICUS advanced NSCLC (SB Goldberg) Trial in progress: RIGAMI-5 Abstract TPS6127 Abstract 8614; Poster board 404 Poster board 583a SC amivantamab + pembrolizumab + carboplatin VS SC amivantamab + chemotherapy with 5-FU + pembrolizumab + cisplatin/carboplatin in 1L R/M COPERNICUS enhanced dermatologic AE prophylaxis in HNSCC (RI Haddad) 2L EGFRm advanced NSCLC (T Leal) SCO #ASCO26 PRESENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) EETING Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org Code are for personal use only and may not be reproduced without ASCO AMERICAN CLINICAL Of permission from ASCO® or the authors of these slides. KNOWLEDGE CONQUERS

Overall Survival CHRYSALIS 2 1L Aml Laz in Alypical EGFR+ 100 NSCLC 85% 80 72% Participants who are surviving (%) 60 55% 40 Median os Median follow-up, 31.3 mo (95% CI) Amivantamab 41.0 mo (27.7-NE) + lazertinib 20 0 15 18 21 24 27 30 33 36 39 42 45 48 51 54 0 3 6 9 12 Months No. at risk 37 36 36 36 34 29 27 26 22 19 15 10 10 8 1 Amivantamab + lazertinib 49 44 37 Copies of this slide deck obtained through Quick Response (QR) ASCO 33 2026 ASCO PRESENTED BY: Joel W Neal Code are for personal use only and may not be reproduced without KNOWLEDGE CONC #ASCO26 permission from ASCO or the authors of these slides. Presentation is property of the author and ASCO. Permission required for reuse: contact permissions@asco.or ANNUAL MEETING --- Radiographic typical EGFR-Mutated Response NSCLC1 With 1L Amivantamab + Lazertinib in CHRYSA - 1L Ami Alypical receive In CHRYSALIS-2 1L amivantamab Cohort + C, lazertinib a total of 49 treatment-naïve participants with atypical EGFR-mutated NSCLC were enrolled globally to NSC Median age was 60 years, 45% were female, and 57% were Asian Most frequent EGFR mutationsᵃ included G719Xb (55%), S768Xc (27%), and L861Xd (24%) Compound mutations were observed in 35% of tumors At a median follow-up of 16.1 months, ORR was 57% CBRe was 84%, and all evaluable patients with >1 post-baseline assessment achieved PR or SD Median DoR was 20.7 months and median PFS was 19.5 months (95% CI, 11.2-NE) 0 -20 Change in SoD of target lesions (%) -40 PR SD -60 -80 -100 reused with permission from Tomasini P, et al. Amivantamab Plus Lazertinib in Atypical EGFR-mutated Advanced Non-Small Cell Lung Cancer Results From CHRYSALIS-2 Journal of Clinical Oncology. 2026,44(1):54-65. Vascopube org/doi/10 1200/JCO-24-02835 Figure Included G719A, G719S, and G719C. Compound mutations were observed in 14 participants. Included S7681 and S768L Compound mutations were observed in 11 participants. Included L861Q All participants L861R, and LB61G included Compound in the ORR mutations analysi " 4 Participants participants. may CBR be is counted defined in as 21 the category. percentage of participants achieving confirmed CR, PR, or durable SD (duration of 211 weeks). Five participants (NE, n=1; PD, n=2; SD, n=2) without a postbaseline tumor assessment are not shown. were 1. Tomasini P, et al. J Clin Oncol. 2026;44(1):54-65. Copies of this slide deck obtained through Quick Response (QR) A Code are for personal use only and may not be reproduced without of these slides. KNO

G CHRYSALIS-2 Study Design CHRYSALIS 2 1L Ami Laz in Atypical EGFR+ NSCLC Dose expansion cohorts Cohort A: EGFR Ex19del or L858R Post-osimertinib and platinum-based chemotherapy Cohort B: EGFR Ex20ins Dose escalation phase Previously reported1 Post-standard of care and platinum-based chemotherapy Primary endpoint: RP2CD was identified: Cohort C: Atypical EGFR mutations IV amivantamab 1050 mg Treatment naive or post-EGFR TKI/chemotherapyᵇ ORR by investigator per (1400 mg if >80 kg)ª RECIST v1.1 Cohort D: EGFR Ex19del or L858R plus Post-osimertinib, biomarker validation Secondary endpoints: DoR Lazertinib 240 mg orally Cohort E: EGFR Ex19del or L858R Post-osimertinib, MET IHC+ analysis (amivantamab + lazertinib) CBRc PFS Cohort F: EGFR Ex19del or L858R OS Post-osimertinib, MET IHC+ analysis (amivantamab monotherapy) Safety (AEs) Participants with Ex20ins and Ex19del/L858R co-mutations were excluded CHRYSALIS-2 enrolled prior to COCOON2, SKIPPirr³, and PALOMA-34 Therefore, participants did not receive the enhanced prophylaxis for dermatologic AEs and IRRs, and subcutaneous amivantamab was not available CHRYSALIS-2 ClinicalTrials gov Identifier: NCT04077463 *Amivantamab was administered intravenously once every week during Cycle 1, with the first dose split between 2 days (350 mg once daily on C1D1, and the remainder on C102) and then every 2 weeks in subsequent cycles. Participants had received 52 previous lines of treatment with chemotherapy and/or second generation EGFR TKI as the most recent line of therapy. °CBR is defined as the percentage of participants achieving confirmed CR, PR, or durable SD (duration of 211 weeks). 1. Tomasini P. et al. J Clin Oncol. 2026,44(1):54-65 2. Cho BC, et al. J Thorac Oncol 2025,20(10):1517-1530. 3. Spira Al, et al J Thorac Oncol 2025,20(6) 809-816. 4. Leight NB, et al. J Clin Oncol 2024;42(30) 3593-3605 2026 ASCO PRESENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) #ASCO26 ASCO AMERICAN SOCIETY OF Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org permission from ASCO or the authors of these slides. KNOWLEDGE CONQUERS CANCER --- Radiographic Response With 1L Amivantamab + Lazertinib in CJ CHRYSALIS 2 1L Aml Laz in Atypical EGFR-Mutated NSCLC¹ Atypical EGFR+ NSCLC In CHRYSALIS-2 Cohort C, a total of 49 treatment-naïve participants with atypical EGFR-mutated NSCLC were enrolled globally to receive 1L amivantamab + lazertinib Median age was 60 years, 45% were female, and 57% were Asian Most frequent EGFR mutationsᵃ included G719Xb (55%), S768Xc (27%), and L861Xd (24%) Compound mutations were observed in 35% of tumors At a median follow-up of 16.1 months, ORR was 57% CBRe was 84%, and all evaluable patients with ≥1 post-baseline assessment achieved PR or SD Median DoR was 20.7 months and median PFS was 19.5 months (95% CI, 11.2-NE) 0 -20 Change in SoD of target lesions (%) -40 PR SD -60 -80 -100 Figure reused with permission from Tomasini P. of al Amivantamab Plus Lazertinib in Alypical EGFR mutated Advanced Non-Small Cell Lung Cancer Results From CHRYSALIS-2 Journal of Clinical Oncology 2026;44(1) 54-65 https://ascopubs.org/doi/10 1200/JCO-24-02835 Participants may be counted in 21 category. Included G719A G719S, and G719C Compound mutations were observed in 14 participants. included S7681 and S768L Compound mutations were observed in 11 participants. included L861Q L861R, and L861G Compound mutations were observed in 4 participants *CBR is defined as the percentage of participants achieving confirmed CR PR or durable SD (duration of 211 weeks). Five participants (NE, n=1; PD, n=2, SD, n=2) without a postbaseline tumor assessment are not shown All participants were included in the ORR analysis. 1. Tomasini P. of al J Clin Oncol 2026,44(1).54-65 2026 ASCO PRESENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) #ASCO26 Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY CUNICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asoo.org permission from ASCO or the authors of these slides. KNOWLEDGE CONQUERS CANCER --- Overall Survival CHRYSALIS- 2 1L Amt az in Alypical EGFR+ NSCLC 100 85% 80 72% Participants who are surviving (%) 60 55% Median os 40 Median follow-up, 31.3 mo (95% CI) Amivantamab 41.0 mo (27.7-NE) + lazertinib 20 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 Months No. at risk Amivantamab lazertinib 49 44 37 37 36 36 36 34 29 27 26 22 19 15 10 10 8 1 0 2026 ASCO PRESENTED BY: Joel W Neal Copies of 745 stide deck obtained through Quick Response (QR) ASCO AMERICAN SOCIETY OF #ASCO26 Code are for personal use only and may not be reproduced without CURRENCAL - ANNUAL MEETING Presentation " property of the author and ASCO Permission required for revse, contact permissions@eson.org permission from ASCO* or the authors of these sades KNOWLEDGE CONQUERS CANCER --- " Conclusions CHRYSALIS-2 N Am L62 in Alypical NSCLC This single-arm study of amivantamab + lazertinib (n=49) in 1L atypical EGFR-mutated advanced NSCLC demonstrates a clinically meaningful median OS of ~3.5 years Responses were durable regardless of demographics, baseline tumor mutations, and disease characteristics With longer follow-up, the safety profile of IV amivantamab + lazertinib was consistent with prior reports¹,², with no new safety signals Amivantamab + lazertinib as a 1L treatment has now shown durable survival in both common and atypical EGFR-mutated advanced NSCLC 1 of a Cin Oncol 2028,44(1) 54 65. 2. Yang OL of N Engl Med 2025,393(17) 1641-1593 2026 ASCO PRE SENTED am Joel W Neal Copies of (74) side Deck obtained through Quick Response (CIR) #ASCO26 Code are for personal use only and may not be reproduced without ASCO INVOICAN SOCIETY DE - - ANNUAL MEETING Presentation property of the author and ASCG Permission - - - contact permissions@wos.org permission from ASCO* or the authors or these skins KNOWLEDGE COMQUERS CANCER

Conclusions CHRYSALIS. 2 1L Ami Laz in Atypical EGFR+ NSCLC This single-arm study of amivantamab + lazertinib (n=49) in 1L atypical EGFR-mutated advanced NSCLC demonstrates a clinically meaningful median os of ~3.5 years Responses were durable regardless of demographics, baseline tumor mutations, and disease characteristics With longer follow-up, the safety profile of IV amivantamab - + lazertinib was consistent with prior reports¹,², with no new safety signals Amivantamab + lazertinib as a 1L treatment has now shown durable survival in both common and atypical EGFR-mutated advanced NSCLC 1. Tomasini P. etal.J Clin Oncol 2026;44(1) 54-65. 2. Yang JCH, et at N Engl Med. 2025,393(17) 1681-1693 2026 ASCO PRE SENTED BY: Joel W Neal #ASCO26 Copies of this slide deck obtained through Quick Response (QR) ANNUAL MEETING Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY OF Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org CLINICAL ONCOLOGY permission from ASCO or the authors of these stides KNOWLEDGE CONQUERS CANCER

CHRYSALIS-2 Study Design Dose expansion cohorts CHRYSALIS-2 Cohort A: EGFR Ex19del or L858R 1L Aml Laz in Atypical EGFR+ Post-osimertinib and platinum-based chemotherapy NSCLC Dose escalation phase Cohort B: EGFR Ex20ins RP2CD was identified: Post-standard of care and platinum-based chemotherapy IV amivantamab 1050 mg Cohort C: Atypical EGFR mutations Previously reported1 (1400 mg if ≥80 kg)a Treatment naïve or post-EGFR TKI/chemotherapyᵇ Primary endpoint: Cohort D: EGFR Ex19del or L858R ORR by investigator per plus RECIST v1.1 Post-osimertinib, biomarker validation Lazertinib 240 mg orally Cohort E: EGFR Ex19del or L858R Secondary endpoints: DoR Post-osimertinib. MET IHC+ analysis (amivantamab + lazertinib) CBRc Cohort F: EGFR Ex19del or L858R PFS Post-osimertinib, MET IHC+ analysis (amivantamab monotherapy) OS Safety (AEs) Participants with Ex20ins and Ex19del/L858R co-mutations were excluded CHRYSALIS-2 enrolled prior to COCOON², SKIPPirr³, and PALOMA-34 Therefore, participants did not receive the enhanced prophylaxis for dermatologic AEs and IRRs, and subcutaneous amivantamab was not available CHRYSALIS-2 ClinicalTrials gov Identifier: NCT04077463 "Amivantamab was administered intravenously once every week during Cycle 1, with the first dose split between 2 days (350 mg once daily on C101, and the remainder on C102) and then every 2 weeks in subsequent cycles. Participants had received <2 previous lines of treatment with chemotherapy and/or second-generation EGFR TKI as the most recent line of therapy. CBR is defined as the percentage of participants achieving confirmed CR, PR or durable SD (duration of 211 weeks). 1. Tomasini P. et al. J Clin Oncol. 2026;44(1):54-65. 2 Cho BC, et al. J Thorac Oncol. 2025,20(10):1517-1530. 3 Spira AI, et al. J Thorac Oncol 2025,20(6).809-816.4. Leight NB, et al. Clin Oncol 2024;42(30).3593-3605. PRE SENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) 026 ASCO Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY CLINICAL ONCOLOGY #ASCO26 permission from ASCO® or the authors of these stides KNOWLEDGE CONQUERS CANCER NNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse: contact permissions@asco.org --- Overall Survival CHRYSALIS 2 mains 100 NOCLC 85% 80 72% Participants who are surviving (%) 60 55% 40 Median os Median follow-up, 31.3 mo (95% CI) Amivantamab + 20 lazertinib 41.0 mo (27.7-NE) 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 No. at risk 51 Months 54 Amivantamab lazertinib 49 44 37 37 36 36 36 34 29 27 26 22 19 15 10 10 8 1 0 2026 ASCO #ASCO26 PRESENTED BY: Joel W Neal ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse contact permissions@ason.org Copies of this sade deck obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO of the authors of these slides ASCO MERCAN CANCAL KNOWLEDGE CONQUERS CANCER --- Subsequent Therapy CHRYSALIS-2 Mysical EGFR+ ROCLC Most participants whose disease had progressed and discontinued 1L treatment were able to receive subsequent therapy (71% [20/28]) The most common subsequent regimens included platinum-based chemotherapy-containing regimens (55%) Amivantam (n=1) 15% EGFR antibody-drug conjugate (n=1) Supportive therapy (n=1) 30% Afatinib (n=2) Other Participants (%) Osimertinib (n=2) Catequentinib (n=1) TKI-based regimens Ruserontinib (n=1) Platinum-based chemotherapy- Carboplatin-pemetrexed (n=4) Cisplatin-pemetrexed (n=1) containing regimens Carboplatin-pernetrexed bevacizumab (n=3) 55% Carboplatin-pemetrexed pembrolizumab (n=1) Carboplatin-pernetrexed ivonescimab (n=1) Carboplatin-paclitaxel + bevacizumab (n=1) Amivantamab + lazertinib (n=20) 2026 ASCO PRE SENTED BY: Joel W Neal Copies of his sade deck obtained through Quick Response (QR) #ASCO26 Code are for personal ine only and may not be reproduced without ASCO CANCAL PHODUCE ANNUAL MEETING Presentation is property of the author and ASCO Permission required or reuse, contact permissions@ason.org permission from ASCO or the authors of these sades KNOWLEDGE CONQUERS CANCER --- Time on Treatment With Baseline Characteristics CHRYSALIS-2 The median duration of treatmentᵃ with 1L amivantamab + lazertinib was 13.3 months (range, <0.1-53.2) Alysical EGFR+ NSCLC 39% of 1L participants remained on treatment for >2 years ≥65y Asian CNS PR SD PD Ongoing FO 0 6 12 18 24 30 36 42 48 54 Time on treatment (months) "Treatment duration is defined as the duration from the day of the first dose of study drug to the day after the last dose of study drug. PRE SENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) ASCO AMERICAN DE 2026 ASCO #ASCO26 Code are for personal use only and may not be reproduced without CLINICAL SHCOLOGY Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco. org. permission from ASCO or the authors of these slides KNOWLEDGE CONQUERS CANCER ANNUAL MEETING

Overall Survival CHRYSALIS 2 1L Ami Laz in Alypical EGFR+ NSCLC 100 85% 80 72% Participants who are surviving (%) 60 55% 40 Median os Median follow-up, 31.3 mo (95% CI) Amivantamab + lazertinib 41.0 mo (27.7-NE) 20 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 No. at risk Months Amivantamab lazertinib 49 44 37 37 36 36 36 34 29 27 26 22 19 15 10 10 8 1 0 2026 ASCO #ASCO26 PRE SENTED BY: Joel W Neal Copies of this slide deck obtained through Quick Response (QR) ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco org. Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY or permission from ASCO® or the authors of these slides. CURICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER --- Time on Treatment With Mutation Type/TP53 Status CHRYSALIS-2 1L Ami Laz in Atypical EGFR+ NSCLC Local data Central data PACC Classical-like TP53mut PR SD PD Ongoing PD 0 6 12 18 24 30 36 42 48 54 Note: Unavailable samples are indicated by grayed-out TOWS in the oncoplot. Time on treatment (months) UT MD Anderson Cancer Center EGFR classification was based on local data If local data were not available, ctDNA collected via central testing was used (cells labeled with asterisk) There was high degree of concordance for participants within both datasets, discrepancies are denoted with a dagger. PACC mutations comprise mutations spanning exons 18-21 including G719X, L747X S7681, L792X and T8541 and have been predicted to after the orientation of the P-loop or helix. Classical like, atypical EGFR mutations are distant from the ATP-binding pocket and are sensitive and selective for all classes of EGFR TKis, ctDNA was collected via central testing and was not available for all participants 1. Robichaux JP, et al. Nature. 2021;597(7878):732-737. 2026 ASCO PRESENTED BY: Joel W Neal Copies of this side deck obtained through Quick Response (QR) #ASCO26 ASCO AMERICAN SOCIETY OF Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org permission from ASCO or the authors of these slides. KNOWLEDGE CONQUERS CANCER --- Uncommon EGFR mutations EGFR Function ATP affinity Prevalence Have varying oncogenic (within EGFR) transformation potential Exon 19 del Remove inhibitory structural Lower ATP 40-50 elements competitiveness Human Tracheobronchial Epithelial Cells 8000, L858R Destabilize the inactive Intermediate 30-40% 7000 (activation) loop Key EGFR 6000 Exon 20 insertions Sterically enforce active Near-wild type ATP 5-10% Colonies 5000 mutations 4000 conformation 3000 affinity 2000 Atypical 1000 0 PACC: G719X, S7681 Alter kinase conformational Variable 6-10% pBp RasV12 wt L858R G719S del ins Non-PACC: L861Q equilibrium EGFR_WT N771_P772naH Robichoux et al. Data from Lung Cancer MDACC, Moffitt, FMI, Guardant, c-bioportal Consortium Singapore/ NCCS K745_E74BinsVPVAIK, N771_PT72mV Exon 20 E746_A7500d Complex Ex20ins atypical Ex19del Common 55.7% 9.1% Common 84.2% insertions D761_E762insEAFQ 9.1% 48.7% Ex 20 ins 4.3% A767_S766insTLA Ex 20 ins 9.1% Ex19del Atypicals 10% V769_D770msASV HITS_V774insAH Atypicals 23.9% 32.7% Other atypical LBSBR V769_D770msGW 12.6% 33.4% V769_D770insMASVO Complex atypical K773_V774mH Classical T790M 3.4% D770_N771ineG L858R atypical 2.2% Ex20ins 23.0% 4.3% T790M 0.3% HIT3_V776insPH Other atypical Classical 6.3% Classical atypical Classical T790M DF70_N771wwGT V774_C775edWV T790M 1.7% 2.1% Figure credit: Dr Jonathan Soon D770_NF71lesSVD LBSBR Total=11,619 Total=3040 Greulich et al. Plos Medicine 2005; Hirose et al. Lung Cancer 2021; Robichoux et al. Natu 2026 ASCO PRESENTED BY: Daniel SW Tan, National Cancer Centre Singapore ASCO AMERICAN CUNICAL #ASCO26 KNOWLEDGE CONQUER ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org --- Selected therapeutic agents in atypical EGFR mutations Trial Phase Drug N= ORR mPFS mDoR OS LUX post hoc Retrospective Afatinib 38 71.1% 10.7 m 11.1 m 19.4 m ACHILLES/TORG1834 Randomised Afatinib 73 61.4% V 47.1% 10.6 mv 5.7 m 10.6 mv 5.6 m NR phase Il HR 0.421 [0.251-0.706] HR 0.348 [0.16-0.758] 40 mg: HR 0.128, p<0.001 30 mg: HR 0.704, P 0.32 KCSG-LU15-09 Phase Il Osimertinib 37 50% 8.2 m 11.2 m NR CNS (n=9) 5.4 m V 9.8 m UNICORN Phase Il Osimertinib 42 55% 9.4 m 22.7 m NR FURTHER Phase lb Firmonertinib 45 160 mg: 43.5% 160 mg: 11.1 m 160 mg: 14.6 m NR 240 mg: 68.2% 240 mg: 16 m 240 mg: NR NCT05256290 Phase Il Silevertinib 43 200 mg: 60% 15.2 m NR NR CHRYSALIS-2 Phase Il Amivantamab- 105 1L: 57% 1L: 19.5 m 1L: 20.7 m 1L: NR Lazertinib 2L: 48% 2L: 7.8 m >2L: 11.0 m >2L: 22.8 m Afatinib is FDA/ EMA approved based on LUX post hoc analysis Osimertinib has been incorporated into guidelines ALPACCA [NCT07185997] : First randomized phase III trial for PACC mutations comparing firmonertinib 240 mg V afatinib/ osimertinib (n=480) Yang TLO 2015; Miura JCO 2025; Cho JCO 2020; Akuma JAMA Oncology 2024; Le WCLC 2025; Tomasini JCO 2025; Black Diamond press release/ Rotow ASCO 2026 2026 ASCO #ASCO26 PRESENTED BY: Daniel SW Tan, National Cancer Centre Singapore ASCO AMERICAN SOCIETY OI ANNUAL MEETING CUNICAL ONCOLOGY Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

ASCO 2026 CHRYSALIS-2 MV Onco 1L Amivantamab + Lazertinib in Atypical EGFR NSCLC Updated Overall Survival Analysis 1 Historically Difficult EGFR Biology EGFR Atypical EGFR mutations historically show inferior outcomes versus classical Can deeper EGFR disease. EGFR pathway suppression Prior afatinib global OS: improve survival? ~19 months 2 Dual EGFR Pathway Suppression Extracellular Blockade Amivantamab Intracellular Lazertinib EGFR-MET Inhibition 3rd-Generation Bispecific Antibody EGFR TKI Biologic dual targeting for uncommon EGFR disease 3 The Survival Headline Median OS 41.0 Months ~3.5 Years Survival 55% 46% alive at 3 years alive at 4 years 4 Long-Term Disease Control 20% Some 7 patients still on beyond continued treatment 4 years >3 years Durable disease suppression appears achievable in selected atypical EGFR tumors. 5 One Core Clinical Takeaway " Atypical EGFR NSCLC may no longer represent a uniformly poor-prognosis EGFR subgroup. Amivantamab lazertinib demonstrated clinically meaningful long-term survival in a historically challenging population. 8 Joel Neal et al ASCO 2026 CHRYSALIS-2 Educational infographic for oncology professionals. Source: Joel Neal Updated Overall Survival Analysis of CHRYSALIS-2. Presented at ASCO 2026.

ASCO 2026 Redefining Atypical EGFR Dual EGFR Blockade in Advanced NSCLC MV ONCO ONE CORE TAKEAWAY Historically difficult atypical EGFR biology Afatinib: ~19-month overall survival Deeper EGFR pathway suppression Extracellular + intracellular inhibition 41-Month OS ~3.5 Years Survival AMIVANTAMAB + LAZERTINIB 55% alive at 3 years 46% alive at 4 years Joel Neal et al ASCO 2026

Efficacy Outcomes of First-line Amivantamab + Lazertinib CHRYSALIS-2 Ami Laz in Atypical EGFR+ NSCLC 0 Investigator-assessed response (n=49) NE PD PD SD SD 17.3 mo -20 Median follow-up (range, 0.1-31.5) (95% CI, 42-71) change In SoD of target leclons -40 57% ORR -60 20.7 mo Median DoR (95% CI, 9.9-NE) -80 PR DoR 26 mo, n (%)* 21 (75) N-100 SD 84% ORR CBR Solitary (95% CI, 70-93) 63% Compound 47% 19.5 mo Median PFS EGFR G7TBX (95% Cl, 11.2-NE) 52% EGFR LS61X 67% EGFR STATE NE 46% Median OS Other (95% Cl, 26.3-NE) 57% The presence of TP53 co-mutation and other pathogenic alterations were not associated with a lower response rate At a median follow-up of 17.3 months, the median PFS was 19.5 months and median OS was NE 4mmg responders CSR 0 defined 15 the percentage of patients achieving condinmed CR PR or durable SD (duration of 211 weeks) PR CSR partial clinical response, benefit SO, stable a confidence disease, internal SoD, sun OR of complete diameters response Dar duration of response; EGFR epidemal growth lador receptor, no, munths, NE, not eslimable/evaluable: ORR objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; 24 ASCO #ASCO24 PRESENTED un Byoung Chul Cho Copies of this slide deck obtained through Quick Response (QR) UAL MEETING ASCO® AMERICAN SOCIETY OF Presentation a property of the author and ASCO. Permission required for contact permissions@daco.com org. Code are for personal use only and may not be reproduced without CUNICAL ONCOLOGY permission from ASCO or the authors of these slides KNOWLEDGE CONQUERS CANCER --- Efficacy Outcomes of Amivantamab + Lazertinib CHRYSALIS-2 Ami Laz in Among All Patients in Cohort C Atypical EGFR+ NSCLC Investigator-assessed response (n=105) 16.1 mo Median follow-up 40 (range, 0.1-31.5) 52% 20 ORR (95% CI, 42-62) 14.1 mo 0 Median DoR (95% CI, 9.5-26.2) DoR 28 mo, n (%)* 38 (69) % change in BOD of target lesions -20 Best response, n (%) -40 CR 0 PR 55 (52) -60 SD 37 (35) -80 Treatment-nalve subgroup PD 8 (8) Previously treated subgroup Not evaluable/UNK 5 (5) -100 79% CBR (95% CI, 70-86) Median PFS 11.1 mo In a heterogeneous population, the median PFS was 11.1 months and median os was NE (95% Cl, 7.8-17.8) NE Median OS (95% CI, 22.8-NE) Rong responders. RSR 0 defined 35 to percentage of patients achieving confirmed CR FR or durable SD (Auration of 211 weeks) CSR oinical will cale, a confidence intenat OR complete response; DOR duration of response; NE, not estimable; ORR, objective response rate: OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; SoD, sum of diameters. ASCO #ASCO24 PRE SENTED or: Byoung Chul Cho Copies of this stide deck obtained through Quick Response (QR) LL MEETING Presentation il property of Do author and ASOO Permission required for rouse, contact permissions@asco erg. Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY permission from ASCO® or the authors of these studes. KNOWLEDGE CONQUERS CANCER

Comparison of First-Line Therapies for NSCLC with Uncommon EGFR Mutations Therapy Trial Mutations Included N PFS (mo) OS ORR Toxicity Summary Afatinib ACHILLES G719X, L861Q, S7681, 109 10.6 (HR Immatu 61% 44% G3+; diarrhea, rash, compound 0.421) re paronychia Osimertinib UNICORN G719X, L861Q, S7681, 40 9.4 Not 55% 27.5% G3+; ILD (12.5%) compound reached Osimertinib KCSG-LU15- G719X, L861Q, S7681 36 8.2 Not 50% Well tolerated 09 reporte d Amivantamab CHRYSALIS- G719X, L861Q, S7681, ~25 19.5 NA 51% Infusion rxn, rash, + Lazertinib 2 others paronychia @SuyogCancer

PRESENTATION . 2026 ASCO Annual Meeting Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Updated. Presenter: Joel W. Neal, MD, PhD Date: May 30, 2026 Abstract: 8501 FROM: Oral Abstract Session Lung Cancer-Non-Small Cell Metastatic

Efficacy Outcomes of First-line Amivantamab + Lazertinib CHRYSALIS-2 Ami Laz in Atypical EGFR+ NSCLC 0 Investigator-assessed response (n=49) NE PD PD SD SD 17.3 mo -20 Median follow-up (range, 0.1-31.5) (95% CI, 42-71) 2-100 change In SOD of target lecions -40 57% ORR -60 20.7 mo Median DoR (95% CI, 9.9-NE) -80 PR DoR 26 mo, n (%)* 21 (75) SD 84% ORR CBR Solitary (95% CI, 70-93) 63% Compound 47% 19.5 mo Median PFS GFR 52% (95% Cl, 11.2-NE) GFR L861X 67% S7GAX 46% NE Median OS 57% (95% CI, 26.3-NE The presence of TP53 co-mutation and other pathogenic alterations were not associated with a lower response rate At a median follow-up of 17.3 months, the median PFS was 19.5 months and median os was NE Menorg CSN 0 delined 35 the permentage of patients achieving confirmed CR PR or durable SD (duration of 11 weeks) PR partial response, SO, stable disease, SoD, sun of diameters CSR clinical boned NOR a confidence and CR complete response Dan duration of response; EGFR epidemal growth lactor receptor, no, months; NE, not estimable/evaluable; ORR objective response rate; OS, overall survival; PD. progressive disease; PFS, progression-free survival; 24 ASCO #ASCO24 PRESENTED un Byoung Chul Cho Copies of this slide deck obtained through Quick Response (QR) UAL MEETING ASCO® AMERICAN SOCIETY OF Presentation a property of the why and ASCO. Permission required for - contact permissions@asoo org. Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY permission from ASCO or the authors of these slides. KNOWLEDGE CONQUERS CANCER

Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2 Presented by: Catherine Shu Abstract #9006 Stage IV NSCLC mutated EGFR ex 19del/L858R Phase 10 Conor day n=162 (Cohort A) - dination Amivantamab + Lazertinib - n=50 evaluable Phase the I I PRIMARY OUTCOME: ORR 33% MEDIAN DOR (MOS) I 9.6 to lines I 149 I Most common grade >3 treatment-related AEs (TRAEs) were infusion-related reactions (7%), turner 1 Exclusion Criteria acneiform dermatitis (5%). and hypoalbuminemia (4%) I mm VO % I Among an unselected population that has exhausted SOC osi and pt-chemo, III III # ami and laz demonstrates encouraging antitumor activity with a + - manageable safety profile https://bit.ly/5N9joqC Created by: @ADesaiMD --- Antitumor Activity of Amivantamab + Lazertinib n/N ORR (95% C) Overall I 54/162 33.3% (26.1%, 41.2%) BICR-assessed Response n=162 Age, years 33/97 34.0% (24.7%, 44.3%) 33% (95% CI, 26-41) <65 ORR >=65 21/65 32.3% (21.2%, 45.1%) Median DOR 9.6 mo (95% Cl, 7.0-NE) Sex Best response, n (%) Male 13/57 22.8% (12.7%, 35.8%) Complete response 2(1) Female 41/105 39.0% (29.7%, 49.1%) Race Partial response 52 (32) Asian 31/99 31.3% (22.4%, 41.4%) Unconfirmed partial response 1 (0.6) Non-Asian 23/63 36.5% (24.7%, 49.6%) Stable disease 69 (43) Baseline ECOG Performance Status Progressive disease 28 (17) 0 17/49 34.7% (21.7%, 49.6%) >=1 NE 10 (6) 37/113 32.7% (24.2%, 42.2%) History of Smoking Clinical benefit rate 57% (95% CI, 49-65) Yes 14/49 28.6% (16.6%, 43.3%) No investigator-assessed ORR=28% (95% CI, 22-36) 40/111 36.0% (27.1%, 45.7%) Prior line of therapy Investigator-assessed median DOR=8.4 mo (95% CI, 5.6-NE) Osimertinib as 1st Line Osimertinib as 2nd Line 8/39 20.5% (9.3%, 36.5%) Median follow-up=10.0 mo (range, 0.3-20.2) Median progression free survival=5.1 mo (95% CI, 4.2-6.9) Heavily treated or out of sequence 24/67 35.8% (24.5%, 48.5%) Mutation Type 22/56 39.3% (26.5%, 53.2%) Median overall survival=14.8 mo (95% CI, 12.1-NE) Exon 19 del Fecentage BOR Meded of policity with confirmed tesponse a Surable dable disease (duration of Exon 21 LBS8R 36/110 32.7% (24.1%, 42.3%) Ottobogy Group m noths and NE, - NR evaluatie, a confidence ORR overal interval response DOR duration rate of response, 11 wooks) ECOG, Eastem Cooperative 18/50 36.0% (22.9%, 50.8%) 0 20 40 60 80 100 2022ASCO 33% #ASCO22 PAY BY DMO ANNUAL MEETING Catherine L is Copies Code of for his dide deck obtained brough Chick Response (QR)

[Slide 1] 10 Conclusions Amivantamab + lazertinib demonstrated durable antitumor activity in patients with EGFRm NSCLC. after progressing on both osimertinib and platinum chemotherapy Treatment Activity is comparable to that in previously reported post-osimertinib, chemotherapy-nalve population, suggesting Benefit that intervening chemotherapy does not impact amivantamab + lazertinib activity ⑉ Safety profile of amivantamab + lazertinib is consistent with prior reports; no new safety signals were identified Safety Among a population that has exhausted standard of care including heavily pretreated patients, amivantamab + lazertinib demonstrated clinically significant and durable antitumor activity, without biomarker selection The CHRYSALIS-2 study (ClinicalTrials.gov Identifier: NCT04077463) is ongoing. and the understanding of underlying resistance mechanisms will be reported at a future meeting Key MARIPOSA (NCT04487080) and MARIPOSA-2 (NCT04988295). ongoing phase 3 randomized trials, are evaluating amivantamab * lazertinib in the frontline and amivantamab + lazertinib carboplatin + pemetrexed in Takeaway post-osimertinib settings and Amivantamab monotherapy upcoming in METex14skip oral presentation (ASCO 2022 #9008) Next Steps EGFRm epidermal growth factor receptor-mutated NSOLC non-small cell lung cancer. 1. Baumi al. Presented at ASCO June 4-8 2024 9006 (onal) 2022 ASCO PRESENTION Capien of this deck ICAS #ASC022 Cinde the Contact of dis presentation is the property of the ASCO Catherine A Shu author licensed ity water Permission required for ANNUAL MEETING ENOWLEDGE CONQUERS CANCER --- [Slide 2] 5 Antitumor Activity of Amivantamab + Lazertinib N/M 044 (95% C) Overall BICR-assessed Response n=162 H 14/042 ORR 33% (95% CI, 26-41) - 3399 14.0% Q2.7% you Median DOR 9.6 mo (95% CI, 7.0-NE) I 21/65 45.1% Best response, n (%) Had 1363 22.8% Complete response 2 (1) H 40/305 29.0% (99.7%) 49.1% Partial response 52 (32) *** 31/99 30.3%% (22.4%) m Unconfirmed partial response 1 (0.6) I 23/43 6.3% 24.7% 48.4% Stable disease 69 (43) Performance Status Progressive disease 28 (17) - 1349 M4%217% 49.6% - 13/01/ 2.2% NE 10 (6) Clinical benefit rate 57% (95% CI, 49-65) DANG 43.3% - 40913 Investigator-assessed ORR=28% (95% CI, 22-36) line of therapy Investigator-assessed median DOR=8.4 mo (95% CI, 5.6-NE) Osimertinio an 1st Line 8/39 20.5% (9.3% 36.5% 24/07 35.8% (34.5% 48.5% Median follow-up=10.0 mo (range, 0.3-20.2) 22/54 13.2% Median progression free survival=5.1 mo (95% CI, 4.2-6.9) Multiation Type (not 29 del Median overall survival=14.8 mo (95% .1-NE) wed 16/110 32.7% Q4.1% 42.3% Exam 21 USSIA use 36.0% (22.9% of patients with confirmed response or durabile stable disease (duration if all works) 20 NO 40 so 300 BICR independent central review CI confidence anthonwal DOR duration of response ECOG Convinent Cooperative Oncology Group months NE ALE evaluable ORR overall 33% ASCO - 2022 of the #ASC022 ASCO Catherine A Shu ANNUAL MEETING --- [Slide 3] CHRYSALIS-2 (ClinicalTrails.gov Identifier: NCT04077463) Study Design Dose Expansion Cohorts RP2CD: Lazertinib 240 mg PO + Amivantamab 1050 mg (1400 mg for >80 kg) IV Endpoints Cohort A: EGFR ex19del or L858R Overall response rate (primary) Post-osimertinib and platinum-based chemotherapy (nu 162) Duration of response Cohort B: EGFR 20ins Clinical benefit rate Post-standard of care and platinum-based chemotherapy Progression-free survival Cohort C: Uncommon EGFR mutations Treatment naive or post-1 or 2nd generation EGFR TKI Overall survival Cohort D: EGFR ex19del or L858R Adverse events Post-osimertinib, chemotherapy naive, biomarker validation Here we present updated safety and efficacy results of the amivantamab and lazertinib combination from fully enrolled Cohort A *Percentage of patients with continued response or durable stable disease (duration of 211 weeks) EGFR growth factor receptor; exticie each 19 deletion es20ins. exon 20 insertion; N. intravenous PO per onal RP2CO recommended phase 2 combination dose TO tyrosine kinane inhibitor 2022 ASCO #ASC022 the property ASCO Catherine A Shu was ANNUAL MEETING